Glysure presents successful clinical trial results at ISICEM

Dateline: 20 March 2012

Intensive Care trial data demonstrates accurate, continuous glucose readings throughout the length of a patient’s stay in Intensive Care 

GlySure Limited, developer of in-hospital continuous blood glucose monitoring systems, announced that it is presenting the results of its Intensive Care Unit (ICU) Pilot Trial for the first time at the 32nd International Symposium on Intensive Care and Emergency Medicine (ISICEM) being held in Brussels, Belgium from March 20th – 23rd, 2012.

The data shows that the optical fluorescence sensor can successfully measure blood glucose levels with a high degree of accuracy across a wide range of intensive care patients throughout their length of stay in the ICU.

The pioneering new research results being presented at ISICEM were collected from critically ill patients during GlySure’s recent pilot ICU clinical trial. It is the first major clinical milestone for the venture capital backed medical technology company.  GlySure believes its continuous intravascular glucose monitoring system has the potential to improve outcomes for over 8 million ICU patients annually.

At ISICEM GlySure CTO Barry Crane and Principal Investigator Dr Krishna Prasad will present the data from eighteen ICU patients with a broad range of conditions and co-morbidities including cardiac surgery, cerebral trauma, sepsis, diabetes and hypertension.  All of the critically ill patients were monitored continuously and accurately for blood glucose levels throughout their length of stay in the ICU – up to 100 hours of continuous monitoring.

“Clinicians have been waiting for a continuous real-time blood glucose monitor to support implementation of Tight Glycemic Control protocols for much of the past decade,” said Dr Prasad.  “Our study demonstrates that it is possible to monitor blood glucose levels continuously and accurately throughout the length of stay of patients in the ICU.”

Commenting before the ISICEM presentation GlySure CEO Chris Jones said: “We are very excited by the results of the pilot ICU clinical trial and are delighted to be able to share them for the first time at ISICEM. We are looking forward to beginning our European and US clinical regulatory trials and bringing this technology to market to support clinicians in realizing the promise of Tight Glycemic Control.”

GlySure’s presentation at ISICEM is entitled ‘Accuracy of a Continuous Intravascular Glucose Monitor in ICU Patients’. An abstract will appear on the ISICEM website at the end of the event. 

Company Contact: Chris Jones, CEO, GlySure. Tel: +44(0)1235 462 870. cjones@glysure.com

Media Contact: Bruce Dodworth, Sea Glass PR. Tel: +44 (0)1780 758555. bruce@seaglasspr.com

Notes to Editors

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).  The company has demonstrated through ICU testing highly accurate sensors which can provide continuous glucose readings throughout the length of a patient’s stay in the ICU.  GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 20 employees.  www.glysure.com

About Tight Glycemic Control (TGC):

In 2001 Greet Van den Berghe demonstrated that controlling patient glucose levels in the ICU within tight normal ranges yielded significant improvements in patient outcomes including a 46 per cent reduction in incidence of sepsis, 41 per cent reduction in renal failure, 50 per cent reduction in blood transfusions, and 34 per cent reduction in mortality.  This study created a new field of medical research with over 100 publications in the past decade including two showing a financial benefit to the hospital in savings of $1,580 to €2,638 per patient.  The challenge for hospitals is that few ICU’s have the resources available to draw blood and perform glucose measurements at the frequency required to safely maintain patients within the target glucose range.

About ISICEM:

The International Symposium on Intensive Care and Emergency Medicine is organised annually by the departments of Intensive Care and Emergency Medicine of Erasme University Hospital, Université Libre de Bruxelles, in association with the Belgian Society of Intensive Care and Emergency Medicine (SIZ). The objectives of this four-day symposium, the largest of its kind worldwide, are to provide participants with a comprehensive, up-to-date review of the most recent, clinically relevant developments in research, therapy, and management of the critically ill. The meeting attracts more than 6,000 physicians, nurses and other healthcare professionals interested in intensive care and emergency medicine and a faculty of 200 well-known experts participate in the various session formats, including lectures, workshops, round tables, 'meet the expert' sessions, pro/con debates, tutorials, and demonstrations.